Perspective Therapeutics presented updated interim results for its Phase 1/2a study of the targeted alpha‑therapy agent [^212Pb]VMT‑α‑NET at the 2026 ASCO‑GI gastrointestinal cancers symposium in San Francisco. The poster highlighted safety data from 56 patients across three dose cohorts and efficacy data from two patients in Cohort 1 (2.5 mCi) and 23 patients in Cohort 2 (5.0 mCi).
Safety analysis showed no new dose‑limiting toxicities and a favorable tolerability profile across all cohorts. Efficacy signals were strongest in the 5 mCi cohort, where objective responses were observed in a majority of the 23 patients evaluated, supporting the dose as the optimal balance of activity and safety. The 6 mCi cohort has completed its dose‑limiting toxicity assessment and the company is cleared to enroll additional patients, with one patient already treated at that level.
The data reinforce the company’s strategy of dose optimization and position the program for a registration‑enabling study. By demonstrating sustained anti‑tumor activity at 5 mCi, the company can move forward with a larger, confirmatory trial while maintaining a manageable safety profile. The ability to enroll more patients at 6 mCi also provides a pathway to explore higher activity levels if needed.
Perspective Therapeutics’ platform is built around the alpha‑emitting isotope 212Pb, which delivers high‑energy radiation directly to neuroendocrine tumor cells via somatostatin receptor targeting. The company is simultaneously developing companion imaging agents that use the same targeting moiety, enabling a theranostic approach that can personalize treatment selection and monitor response. Recent FDA guidance on radiopharmaceutical dosing has clarified that higher renal doses can be acceptable when supported by dosimetry, giving the company additional flexibility in dose design.
Investors responded positively to the data acceptance for presentation at ASCO‑GI, viewing the clinical progress as a clear signal of momentum in the company’s pipeline. The presentation also marked the first new clinical information since the October 2025 ESMO update, further reinforcing the company’s trajectory toward a registration‑enabling study.
Chief Medical Officer Markus Puhlmann said the interim results “continue to support VMT‑α‑NET’s compelling overall clinical profile at the 5 mCi dose” and that the company is “well positioned to engage with regulators in 2026” for a registrational trial. Chief Executive Officer Thijs Spoor added that the program’s progress “reflects the strength of our targeted radiopharmaceutical platform and our growing capabilities as a clinical‑stage oncology company.”
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.